Kailos Genetics Announces Co-marketing Agreement with Illumina, Inc. for Pharmacogenetics Solution for Research
Agreement expands Kailos’ use of market-leading next-generation sequencing solutions March 21, 2017 06:00 AM Pacific Daylight Time HUNTSVILLE, Ala.–(BUSINESS WIRE)–Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced it has entered into a co-marketing agreement with Illumina, Inc. (NASDAQ: ILMN). Under the terms of the... Read more